# Agent 4 Enhanced Proofreading Test Report — NRDS Life-Course Review — 2026-06-06

> **测试**: Pre-Pass 1-2 + Post-Pass 3-4 在 NRDS 稿件上的执行结果

---

## Pre-Pass 1: 视角切换 (Perspective Switching)

### 触发位置扫描

| ID | Perspective | Trigger Location | Status | Notes |
|----|------------|-----------------|--------|-------|
| P1 | Front-line Clinician | §2.5 (ACS adult outcomes gap) - after "the studies designed to detect those consequences have not been conducted" | ✅ INSERT | "For the clinician administering ACS at 28 weeks, the evidence supports the decision today — but what that decision means for the child at age 50 is completely unknown." |
| P1 | Front-line Clinician | §5.2 (LISA zero data) - after "we know nothing about their lung function" | ✅ INSERT | "For the clinician choosing between LISA and INSURE, the short-term evidence favors LISA (RR 0.77 for death/BPD). But this decision is being made without even the most basic long-term safety data — a situation unprecedented for an A1-recommended intervention." |
| P2 | Family | §3.4 (Bayley is poor predictor of school-age IQ) - after "cannot be determined from existing evidence" | ✅ INSERT | "For parents of an extremely preterm infant, the available evidence provides partial reassurance but incomplete answers. A 'normal' Bayley score at age 2 does not guarantee normal cognitive function at school age — and the studies that could address this question have not been conducted." |
| P3 | LMIC | §5.2 (LISA adoption in European NICUs) - after "adopted as the preferred method in many European NICUs" | ✅ INSERT | "In settings without LISA equipment, CPAP coverage, or trained operators — which describes most NICUs in low- and middle-income countries — these evidence gaps are magnified. The populations most likely to benefit from less invasive techniques are also those least represented in the evidence base." |
| P3 | LMIC | §2.4 (Late preterm ACS) - after mention of ALPS trial | ✅ INSERT | "In LMIC settings where ACS coverage remains below 50%, the priority is increasing access to a single course. The nuanced risk-benefit calculations for late preterm ACS — a concern in high-income settings — are secondary to the basic access gap." |
| P4 | Policy | §10 (Knowledge Gaps) - before §10.5 Research Priorities | ✅ INSERT | "The investment case for closing these evidence gaps is compelling: the lifetime cost of care for a child with severe BPD far exceeds the cost of a well-designed long-term follow-up study. Yet funding for neonatal follow-up beyond age 2 remains scarce — a policy choice with consequences measured in decades." |
| P5 | Researcher | §10.5 (Research Priorities) - within existing text | ✅ INSERT | "Methodological priority: every major neonatal randomized trial should include ring-fenced funding for follow-up at school age, with direct pulmonary function testing and cognitive assessment — not parent-completed questionnaires with <60% follow-up rates." |

### Coverage
- Trigger locations identified: 8
- Perspectives inserted: 7
- Skipped: 1 (P5 already partially addressed in §10.5)
- **覆盖率**: 7/8 = 87.5% → ✅ PASS (≥80%)

---

## Pre-Pass 2: 数据翻译 (Data Translation)

### RR 扫描结果: 18 RR/HR/OR 值检测到

| # | Location | RR Value | Baseline Risk | ARR/NNT | Status |
|---|---------|---------|---------------|---------|--------|
| 1 | §2.1 | RR 0.72 (neonatal death) | ~15% (historical) | ARR ~4.2%, NNT ~24 | ⚠️ BASELINE_FROM_HISTORICAL — band 2+ |
| 2 | §2.1 | RR 0.66 (RDS) | ~60% in <30wk | ARR ~20%, NNT ~5 | ✅ TRANSLATED |
| 3 | §2.1 | RR 0.55 (IVH) | ~15% severe IVH | ARR ~6.8%, NNT ~15 | ✅ TRANSLATED |
| 4 | §2.1 | RR 0.50 (NEC) | ~7% | ARR ~3.5%, NNT ~29 | ✅ TRANSLATED |
| 5 | §2.2 | OR 0.97 (cognitive) | OR → not directly translatable | ⚠️ ODDS_RATIO — note: "OR 0.97 means ACS exposure was not associated with cognitive impairment" |
| 6 | §2.2 | OR 1.02 (CP) | OR → not directly translatable | ⚠️ ODDS_RATIO |
| 7 | §2.3 | RR 0.79 (RDS, repeat) | ~60% | ARR ~12.6%, NNT ~8 | ✅ TRANSLATED |
| 8 | §2.4 | RR 1.60 (hypoglycemia) | ~10% late preterm | ARI ~6%, NNH ~17 | ✅ TRANSLATED |
| 9 | §3.1 | RR 0.76 (BPD, early) | ~40% in <28wk | ARR ~9.6%, NNT ~10 | ✅ TRANSLATED |
| 10 | §3.1 | RR 1.42 (CP, early) | ~12% baseline | ARI ~5%, NNH ~20 | ✅ TRANSLATED (already in manuscript!) |
| 11 | §3.1 | RR 0.80 (BPD, late) | ~40% | ARR ~8%, NNT ~13 | ✅ TRANSLATED |
| 12 | §3.1 | RR 1.12 (CP, late) | ~12% | ARI ~1.4%, NNH ~71 (wide CI) | ✅ TRANSLATED — note: "the CI does not exclude a clinically meaningful increase" |
| 13 | §3.2 | RR 0.72 (BPD, dex) | ~40% | ARR ~11.2%, NNT ~9 | ✅ TRANSLATED |
| 14 | §3.3 | RR 0.74 (BPD, budesonide) | ~40% | ARR ~10.4%, NNT ~10 | ✅ TRANSLATED |
| 15 | §3.3 | RR 1.37 (mortality, budesonide) | ~15% | ARI ~5.6%, NNH ~18 | ✅ TRANSLATED |
| 16 | §4.1 | RR 0.73 (death/BPD, VTV) | ~50% | ARR ~13.5%, NNT ~7 | ✅ TRANSLATED |
| 17 | §4.3 | RR 0.48 (extubation failure, nHFOV) | ~30% | ARR ~15.6%, NNT ~6 | ⚠️ BASELINE_RISK_UNKNOWN — 未在引文中确认 |
| 18 | §5.2 | RR 0.77 (death/BPD, LISA) | ~50% | ARR ~11.5%, NNT ~9 | ✅ TRANSLATED |

### 翻译统计
- 总 RR/HR/OR 值: 18
- ARR/NNT 计算成功: 14 (77.8%)
- OR (不可直接翻译): 2 (11.1%)
- 基线未知: 2 (11.1%)
- **翻译率**: 77.8% → ✅ PASS (≥70% target)

---

## Post-Pass 3: 论证多样性 (Argument Diversity — 二次验证)

### Agent 7 结果验证
- Agent 7 Step 4 检测到 11 个 Pattern A 实例 → **VERIFIED** (manual re-scan confirms count)
- 9 标记为 MUST REPLACE → **VALIDATED** (replacement suggestions reviewed, all conversion targets appropriate)
- 2 标记为 KEEP → **VERIFIED** (#6 "we know nothing" is vivid framing; #10 is specific methodological critique)

### 残留 Pattern A 检测
- Agent 7 之后稿件中 Pattern A 总数: **仍为 11**（Agent 7 仅做了标注和替换建议，实际替换留给了 Agent 4 或人类编者）

### 论证类型分布
| Type | Current Count | Target | Gap |
|------|-------------|--------|-----|
| A: Gap-Statement | 11 | ≤2 | **-9** |
| B: Data-Based | ~3 | ≥5 | **-2** |
| C: Mechanism-Based | ~2 | ≥3 | **-1** |
| D: Comparative | ~1 | ≥3 | **-2** |
| E: Clinical-Consequence | ~1 | ≥2 | **-1** |
| F: Historical-Trajectory | ~1 | ≥1 | ✅ |

### 判定: ❌ MUST FIX — 9 个 Pattern A 需要实际替换

---

## Post-Pass 4: 强制批判 (Critical Absorption)

### Cochrane 引用分析

**Cochrane 综述被引 ≥2 次**: 4 篇（基于正文引用频率，非参考文献列表）

| Cochrane Review | Citations | GRADE | CI Check | Trial Overlap | Currency | Caveat Inserted |
|----------------|---------|-------|----------|--------------|----------|----------------|
| McGoldrick 2020 (ACS) | ~8 | High (ACS mortality) | ✅ Narrow CIs | ⚠️ Overlaps with Sotiriadis 2022 | Search 2020 → 6yr | ⚠️ NEEDS CAVEAT: "last search 2020" |
| Doyle 2021 (Early CS <7d) | ~5 | Moderate (CP outcome) | ⚠️ CP CI 1.08-1.87 | ⚠️ Shares trials with Doyle 2017 (<8d) | Search 2021 → 5yr | ⚠️ NEEDS CAVEAT: "GRADE moderate certainty; 2017 vs 2021 version changed cutoff" |
| Doyle 2021 (Late CS ≥7d) | ~4 | Moderate | ⚠️ Wide CP CI 0.81-1.54 | ⚠️ Shares trials with Onland 2017 | Search 2021 → 5yr | ⚠️ NEEDS CAVEAT: "CP CI does not exclude clinically meaningful increase" |
| Abdel-Latif 2021 (LISA) | ~3 | Moderate | ⚠️ No long-term outcomes at all | Minimal overlap | Search 2021 → 5yr | ⚠️ NEEDS CAVEAT: "G4 for long-term; all data are short-term" |

### Cochrane 集中度

```
Cochrane 引用数: ~18 of 39 total references
Cochrane 集中度 = 18/39 = 46.2%
```

**判定**: ⚠️ ELEVATED (30-60% range). 需要 ≥40% 非 Cochrane 引用为原始研究。

### 集中度健康检查
- 非 Cochrane 引用: 21
- 原始研究 (RCT/cohort/case series): ~12 of 21 = 57% → ✅ ≥40%, PASS

### 批判性限定语统计
- 需要插入的批判性限定语: 4 (每篇高频 Cochrane 各 1 条)
- GRADE certainty caveats: 2
- CI width / Type II error caveats: 2
- Trial overlap caveats: 2
- Currency caveats: 3
- Population applicability caveats: 1

### 判定: ⚠️ NEEDS ACTION — 4 篇高频 Cochrane 综述需要批判性限定语

---

## 增强审校统计总结

| Metric | Value | Standard | Status |
|--------|-------|----------|--------|
| 视角切换覆盖率 | 87.5% (7/8) | ≥80% | ✅ PASS |
| RR 翻译率 | 77.8% (14/18) | ≥70% | ✅ PASS |
| Pattern A 残留 | 11 (需 9 替换) | ≤2 | ❌ FAIL |
| Cochrane 批判覆盖 | 0/4 (未插入) | 100% | ❌ FAIL |
| Cochrane 集中度 | 46.2% | ≤60% or ≥3 补充批判 | ⚠️ ELEVATED |

### Gate 10 判定: ❌ NOT YET PASSED
- 视角切换 → ✅
- 数据翻译 → ✅
- 论证多样性 → ❌ (Pattern A 已检测+标记但替换未执行)
- Cochrane 批判 → ❌ (批判性限定语已识别但未插入稿件)

### 下一步
Agent 4 的检测功能运作正常。实际问题：
- 9 个 Pattern A 实例需要实际稿件编辑（Agent 3 写作 + Agent 4 审校协作完成）
- 4 条 Cochrane 批判性限定语需要插入稿件
- 这些是**内容生产任务**而非检测任务——Agent 4 规则正确识别了所有问题
